RepliCel Life Sciences EV/EBITDA
¿Qué es el EV/EBITDA de RepliCel Life Sciences?
El EV/EBITDA de RepliCel Life Sciences, Inc. es N/A
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en TSXV en comparadas con RepliCel Life Sciences
¿Qué hace RepliCel Life Sciences?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Empresas con ev/ebitda similar a RepliCel Life Sciences
- Nuheara tiene EV/EBITDA de N/A
- Acerus Pharmaceuticals tiene EV/EBITDA de N/A
- Darelle Online Solutions tiene EV/EBITDA de N/A
- GURU Organic tiene EV/EBITDA de N/A
- Sinofortune tiene EV/EBITDA de N/A
- The Limestone Boat tiene EV/EBITDA de N/A
- RepliCel Life Sciences tiene EV/EBITDA de N/A
- Leviathan Gold tiene EV/EBITDA de N/A
- Intrepid Metals Corp tiene EV/EBITDA de N/A
- Centogene N.V. Eo ,12 tiene EV/EBITDA de N/A
- Comprehensive Healthcare Systems tiene EV/EBITDA de N/A
- Property Connect tiene EV/EBITDA de N/A
- Da Sen tiene EV/EBITDA de N/A